Identification

Name
MN-305
Accession Number
DB05339
Type
Small Molecule
Groups
Investigational
Description

MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).

Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 379.835
Monoisotopic: 379.118650526
Chemical Formula
C19H22ClNO5
InChI Key
GGNCUSDIUUCNKE-RSAXXLAASA-N
InChI
InChI=1S/C19H21NO5.ClH/c1-2-5-18-16(4-1)22-12-15(25-18)11-20-8-3-9-21-14-6-7-17-19(10-14)24-13-23-17;/h1-2,4-7,10,15,20H,3,8-9,11-13H2;1H/t15-;/m0./s1
IUPAC Name
[3-(2H-1,3-benzodioxol-5-yloxy)propyl][(2S)-2,3-dihydro-1,4-benzodioxin-2-ylmethyl]amine hydrochloride
SMILES
Cl.C(CNC[[email protected]]1COC2=CC=CC=C2O1)COC1=CC2=C(OCO2)C=C1

Pharmacology

Indication

Investigated for use/treatment in anxiety disorders, depression, insomnia, and neurologic disorders.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development by MediciNova both for the treatment of insomnia, as well as for anxiety disorders such as Generalized Anxiety Disorder (GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed no evidence of inducing genetic mutations, immune response or cancer. MN-305 has also proved to be consistently well-tolerated in clinical safety, efficacy and pharmacokinetic studies in over 1,200 subjects.

TargetActionsOrganism
U5-hydroxytryptamine receptor 1ANot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Kittner B: Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group. Alzheimer Dis Assoc Disord. 1999 Oct-Dec;13 Suppl 3:S166-71. [PubMed:10609697]
External Links
PubChem Compound
198746
PubChem Substance
175426979
ChemSpider
172022

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP2.51ChemAxon
pKa (Strongest Basic)9.1ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area58.18 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity90.59 m3·mol-1ChemAxon
Polarizability37.06 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9919
Blood Brain Barrier+0.8608
Caco-2 permeable-0.5296
P-glycoprotein substrateSubstrate0.6609
P-glycoprotein inhibitor IInhibitor0.6324
P-glycoprotein inhibitor IIInhibitor0.6917
Renal organic cation transporterNon-inhibitor0.5443
CYP450 2C9 substrateNon-substrate0.8682
CYP450 2D6 substrateNon-substrate0.5908
CYP450 3A4 substrateNon-substrate0.5468
CYP450 1A2 substrateInhibitor0.847
CYP450 2C9 inhibitorNon-inhibitor0.8063
CYP450 2D6 inhibitorInhibitor0.6393
CYP450 2C19 inhibitorNon-inhibitor0.5995
CYP450 3A4 inhibitorInhibitor0.7406
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7527
Ames testNon AMES toxic0.5577
CarcinogenicityNon-carcinogens0.9219
BiodegradationNot ready biodegradable0.9284
Rat acute toxicity2.6018 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6893
hERG inhibition (predictor II)Non-inhibitor0.5399
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzo-1,4-dioxanes. These are heterocyclic compounds containing a benzene ring fused to a 1,4-dioxane ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodioxanes
Sub Class
Benzo-1,4-dioxanes
Direct Parent
Benzo-1,4-dioxanes
Alternative Parents
Benzodioxoles / Alkyl aryl ethers / Para dioxins / Benzenoids / Oxacyclic compounds / Dialkylamines / Acetals / Organopnictogen compounds / Hydrochlorides / Hydrocarbon derivatives
Substituents
Benzo-1,4-dioxane / Benzodioxole / Alkyl aryl ether / Benzenoid / Para-dioxin / Acetal / Oxacycle / Secondary aliphatic amine / Secondary amine / Ether
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da

Drug created on November 18, 2007 11:24 / Updated on December 01, 2017 15:35